Monthly Archives: September 2015
Testing and Toxicology of Designer Drugs
This article explains Testing and Toxicology of Designer Drugs and the scientific, legal or practical evidence readers should understand.
This article explains Testing and Toxicology of Designer Drugs and the scientific, legal or practical evidence readers should understand.
A laboratory can quantify total drug in plasma while struggling to quantify the much smaller unbound portion. That difference can determine whether a pharmacokinetic study answers its question. A result reported as not statistically significant does not resolve the question when the measurements are too limited to detect a meaningful…
Read Article: Total and Unbound Drug Concentrations: What a Fasting Study Could Not Resolve
A medication can be associated with a different drug response because of the condition it was prescribed to treat. That possibility matters when interpreting a concentration-response model as evidence of a pharmacodynamic interaction. Franken and colleagues examined this problem in a study of midazolam sedation in terminally ill adults. Their…
Read Article: Midazolam Sedation Models: Why a Medication Association Does Not Prove Antagonism
A cannabinoid detected after dosing stops is evidence of analytical persistence. It does not, by itself, establish an exact elimination half-life, the time of the last dose or a universal date when another person’s sample will test negative. A controlled study by Wolinsky and colleagues helps explain the distinction. Published…
Read Article: CBD After Repeated Dosing: Why Detectability Does Not Establish a Washout Deadline